Besides analysis of CTCs, expression of androgen receptor splice variant 7 (AR-V7) in CTCs of prostate cancer patients has gained clinical interest for prediction of non-response to androgen receptor-targeted agents (ARTAs), i.e., abiraterone or enzalutamide4–7. Here, AR is linked to prostate cancer.